Emerging Radionuclides in a Regulatory Framework for Medicinal Products - How Do They Fit?

European Pharmacopeia directive 2001/83 medicinal product radionuclide precursor radionuclides regulatory theranostics

Journal

Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047

Informations de publication

Date de publication:
2021
Historique:
received: 09 03 2021
accepted: 04 05 2021
entrez: 14 6 2021
pubmed: 15 6 2021
medline: 15 6 2021
Statut: epublish

Résumé

Recent years have seen the establishment of several radionuclides as medicinal products in particular in the setting of theranostics and PET. [

Identifiants

pubmed: 34124109
doi: 10.3389/fmed.2021.678452
pmc: PMC8192700
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

678452

Informations de copyright

Copyright © 2021 Decristoforo, Neels and Patt.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Molecules. 2019 Apr 03;24(7):
pubmed: 30987141
Nucl Med Commun. 2015 May;36(5):414-22
pubmed: 25646703
EJNMMI Radiopharm Chem. 2017;1(1):1
pubmed: 29564378
Eur Urol. 2021 Mar;79(3):343-350
pubmed: 33293081
Q J Nucl Med Mol Imaging. 2017 Jun;61(2):135-144
pubmed: 28124548
EJNMMI Radiopharm Chem. 2017;1(1):12
pubmed: 29564388
J Hematol Oncol. 2020 Oct 28;13(1):144
pubmed: 33115529
Rev Med Suisse. 2015 Jun 17;11(479):1340-4
pubmed: 26255495
Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2175-85
pubmed: 25081821
Pharmaceutics. 2020 Dec 31;13(1):
pubmed: 33396374
Semin Nucl Med. 2019 Sep;49(5):450-457
pubmed: 31470937
EJNMMI Radiopharm Chem. 2019 Jan 11;4(1):2
pubmed: 31659485
EJNMMI Radiopharm Chem. 2021 Feb 12;6(1):8
pubmed: 33580358
J Labelled Comp Radiopharm. 2019 Aug;62(10):673-683
pubmed: 30741441
J Labelled Comp Radiopharm. 2014 Aug;57(10):615-20
pubmed: 25196257
Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1808-1819
pubmed: 32409894
J Labelled Comp Radiopharm. 2019 Aug;62(10):615-634
pubmed: 31137083
Cancer Biother Radiopharm. 2018 Oct;33(8):316-329
pubmed: 30265573
J Nucl Med. 2019 Sep;60(Suppl 2):13S-19S
pubmed: 31481583
Br J Radiol. 2018 Nov;91(1091):20180074
pubmed: 29658792
Front Pharmacol. 2018 Sep 04;9:996
pubmed: 30233374
EJNMMI Radiopharm Chem. 2019 May 22;4(1):10
pubmed: 31659486
EJNMMI Radiopharm Chem. 2019 Aug 20;4(1):22
pubmed: 31659572
Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1781-1794
pubmed: 29725717
Med Etika Bioet. 2002 Spring-Summer;9(1-2):12-9
pubmed: 16276663

Auteurs

Clemens Decristoforo (C)

Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria.

Oliver Neels (O)

Department of Radiopharmaceuticals Production, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.

Marianne Patt (M)

Department for Nuclear Medicine, Radiochemistry, University of Leipzig, Leipzig, Germany.

Classifications MeSH